Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBT Margin (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed EBT Margin for 5 consecutive years, with 370.79% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin changed N/A year-over-year to 370.79%, compared with a TTM value of 430.73% through Sep 2025, up 212176.0%, and an annual FY2024 reading of 2165.36%, up 1010802.0% over the prior year.
  • EBT Margin was 370.79% for Q3 2025 at Autolus Therapeutics, down from 227.12% in the prior quarter.
  • Across five years, EBT Margin topped out at 2071.96% in Q1 2022 and bottomed at 130715.0% in Q4 2024.
  • Average EBT Margin over 4 years is 18112.44%, with a median of 639.06% recorded in 2025.
  • The sharpest move saw EBT Margin crashed -515439bps in 2023, then soared 256067bps in 2024.
  • Year by year, EBT Margin stood at 2071.96% in 2022, then tumbled by -645bps to 11298.03% in 2023, then plummeted by -1057bps to 130715.0% in 2024, then surged by 100bps to 370.79% in 2025.
  • Business Quant data shows EBT Margin for AUTL at 370.79% in Q3 2025, 227.12% in Q2 2025, and 756.36% in Q1 2025.